Marketing an aesthetic practice under UK advertising law
Why prescription-only injectables cannot be advertised to the public in the UK, what the CAP Code and Human Medicines Regulations require, and what may be said instead.
Digital marketing guidance written for general small businesses does not transfer to aesthetic practice in the United Kingdom, because one of the products involved is a prescription-only medicine and prescription-only medicines cannot lawfully be advertised to the public. This is the single rule that most frequently catches new practices, and it is not a matter of tone or taste. It is a statutory prohibition with a separate advertising code sitting on top of it.
The two instruments
Regulation 284 of the Human Medicines Regulations 2012 prohibits the advertising of prescription-only medicines to the general public. Breach is a criminal offence, enforced by the Medicines and Healthcare products Regulatory Agency.
CAP Code rule 12.12 restates the prohibition in advertising terms: marketing communications must not promote a prescription-only medicine to the public. The Committee of Advertising Practice writes the code; the Advertising Standards Authority adjudicates against it, and its remit covers advertisers’ own websites and their social media accounts, not only paid media.
Botulinum toxin products are prescription-only medicines. Dermal fillers, in contrast, are regulated as medical devices and are not caught by this particular prohibition — though every other advertising requirement, including the prohibition on misleading claims and on exaggerating results, still applies to them.
What counts as advertising
The scope is wider than most practices assume. It includes the practice website, service and price lists, paid search advertising, organic social media posts, stories and reels, before-and-after images captioned with the product name, hashtags containing brand names, replies to comments, and material posted by influencers on the practice’s behalf. Enforcement activity has focused heavily on social media. CAP and the MHRA have issued a joint enforcement notice to the beauty and cosmetic services industry, and the ASA now uses monitoring technology to find non-compliant posts automatically. The naming of a specific brand is the clearest breach, but it is not the only one. Referring to the product category in a way that identifies a prescription-only medicine — including thinly disguised spellings, emoji substitutions and abbreviations — is treated as promotion of that medicine.
What may be said instead
Three principles cover most cases.
Advertise the consultation, not the medicine. A practice may promote the fact that it offers consultations for facial ageing concerns, that a prescriber is available, and that treatment options will be discussed at that appointment. The offer being advertised is the professional service.
Use generic, non-identifying terminology. “Anti-wrinkle injections” is the term generally accepted in this context, because it describes an outcome category rather than naming a prescription-only product. Wording that pairs a generic term with a brand name, or that makes the brand obvious from context, defeats the purpose.
Answer, do not promote. Providing factual information to a patient who has already entered a consultation is different from broadcasting that information to the public. The prohibition attaches to promotional communication directed at the public, not to clinical discussion with an individual patient.
Price lists deserve particular attention: publishing a price against a named prescription-only medicine is promotion of that medicine, and time-limited discounting of it compounds the problem by encouraging demand for a product that must be individually prescribed.
Sanctions
The ASA can rule against an advertiser, publish that ruling, require the advertisement to be withdrawn, and apply sanctions including withdrawal of paid search advertising and referral to statutory bodies. The MHRA can issue enforcement notices and, in serious cases, pursue criminal prosecution. Professional regulators may treat non-compliant advertising as a fitness-to-practise matter independently of either.
The practical position is that compliant marketing for an aesthetic practice is built around the practitioner, the consultation and the concern being addressed, rather than around a named product.
